SEOUL, South Korea I August 11, 2025 I AMI Pharm, a biotechnology company focused on aesthetic and therapeutic innovations, announced today that its lead ...

EAST HANOVER, NJ, USA I August 11, 2025 I Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults ...

BASEL, Switzerland I August 11, 2025 I FoRx Therapeutics, a clinical-stage biotechnology company developing precision anti-cancer therapeutics, today ...

HONG KONG, China I August 10, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, ...

STUTTGART, Germany I August 11, 2025 I Selecting the right target remains the most important decision to make in drug discovery and has to be seen in light of ...

YANTAI, China I August 8, 2025 I On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration ...

ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...

Topline results from CATT1 Phase 3 trial expected in second half of 2026. HIGH POINT, NC, USA I August 07, 2025 I vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceuti ...

PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcer ...

Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart ...

AHMEDABAD, India I August 7, 2025 I Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified ...